Article Dans Une Revue OncoImmunology Année : 2020

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

Quentin Scanvion
Johana Béné
  • Fonction : Auteur
Sophie Gautier
  • Fonction : Auteur
Aurélie Grandvuillemin
  • Fonction : Auteur
Christine Le Beller
  • Fonction : Auteur
Chouki Chenaf
Nicolas Etienne
  • Fonction : Auteur
Solenn Brousseau
  • Fonction : Auteur
Alexis B Cortot
  • Fonction : Auteur
Laurent Mortier
Franck Morschhauser
  • Fonction : Auteur
Alexandra Forestier
  • Fonction : Auteur
Matthieu Groh
  • Fonction : Auteur
David Launay
  • Fonction : Auteur
Eric Hachulla
  • Fonction : Auteur
Myriam Labalette
  • Fonction : Auteur
Jean-Emmanuel Kahn
  • Fonction : Auteur
Guillaume Lefèvre
  • Fonction : Auteur
  • PersonId : 1067897

Résumé

A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilance database. Thirty-seven reports of eosinophilia induced by treatment with immune checkpoint inhibitors (ICIs) were included. The median [range] time to the absolute eosinophil count (AEC) peak was 15 [4─139] weeks. The median AEC was 2.7 [0.8─90.9] G/L. Eosinophil-related manifestations were reported in 21 of the 37 cases (57%). If administered, corticosteroids were always effective (n = 10 out of 10). Partial or complete remission of eosinophilia was obtained in some patients not treated with corticosteroids, after discontinuation (n = 12) or with continuation (n = 4) of the ICI. The AEC should be monitored in ICI-treated patients. If required by oncologic indications, continuation of ICI may be an option in asymptomatic hypereosinophilic patients, and in corticosteroid responders.

Fichier principal
Vignette du fichier
koni-09-01-1722022.pdf (936.68 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-05285559 , version 1 (26-09-2025)

Licence

Identifiants

Citer

Quentin Scanvion, Johana Béné, Sophie Gautier, Aurélie Grandvuillemin, Christine Le Beller, et al.. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. OncoImmunology, 2020, 9, ⟨10.1080/2162402x.2020.1722022⟩. ⟨hal-05285559⟩
50 Consultations
55 Téléchargements

Altmetric

Partager

  • More